Revance Therapeutics, Inc.

RVNC

US7613301099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 28/06/2024 BST			5-day change	1st Jan Change
2.57 ^USD	-0.39%		-3.38%	-70.76%

06-24	Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from S&P Pharmaceuticals Select Industry Index	CI
06-11	Transcript : Revance Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM

Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from S&P Pharmaceuticals Select Industry Index

June 23, 2024

Latest news about Revance Therapeutics, Inc.

Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from S&P Pharmaceuticals Select Industry Index	06-23	CI
Transcript : Revance Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM	06-11
Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	05-10	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	05-10	MT
Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, vs. Street Est of $56.7M	05-09	MT
Revance Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Transcript : Revance Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia	05-09	CI
Certain Restricted Stock Units of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	05-03	CI
Certain Common Stock of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.	05-03	CI
AbbVie raises annual profit forecast on strong Skyrizi sales	04-26	RE
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	04-12	CI
Transcript : Revance Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:30 AM	03-12
North American Morning Briefing: Stock Futures Fall With Investor Focus on Inflation Data	03-11	DJ
Revance Therapeutics Prices $100 Million Public Offering	03-04	MT
Goldman Sachs Adjusts Price Target on Revance Therapeutics to $9 From $8, Maintains Neutral Rating	03-01	MT
Needham Cuts Price Target on Revance Therapeutics to $18 From $20, Maintains Buy Rating	02-29	MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $20 From $42, Maintains Overweight Rating	02-29	MT
Transcript : Revance Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	02-28
Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q4 Revenue $69.8M	02-28	MT
Revance Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	02-28	CI
Revance Therapeutics, Inc. Announces Executive Changes	02-28	CI
Revance Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28	CI
Revance Therapeutics Gets Permanent J-Code for Daxxify	02-02	DJ
Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology	02-02	CI

Chart Revance Therapeutics, Inc.

Duration

Period

More charts

Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.

Sector

Pharmaceuticals

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Revance Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.57 USD

Average target price

13.5 USD

Spread / Average Target

+425.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
REVANCE THERAPEUTICS, INC.	-70.76%	268M
CSL LIMITED	+2.99%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-4.34%	37.55B
BIOGEN INC.	-10.41%	33.75B
UCB	+75.79%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-14.61%	15.63B
INCYTE CORPORATION	-3.46%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.31%	11.5B
ALTEOGEN INC.	+184.77%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.13%	9.23B

Biopharmaceuticals